Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 2/2016

01-02-2016 | Original Article

Enhanced anti-tumor effects of doxorubicin on glioma by entrapping in polybutylcyanoacrylate nanoparticles

Authors: Yuebin Zhang, Jia Yu, Lifeng Zhang, Jiabin Cai, Doute Cai, Chengjie Lv

Published in: Tumor Biology | Issue 2/2016

Login to get access

Abstract

For effective therapy for glioma, it is essential for chemotherapeutics to pass the blood-brain barrier to target glioma cells with little side effects to surrounding normal cells. In this study, we prepared doxorubicin-polybutylcyanoacrylate nanoparticles (Dox-PBCA-NP) and assessed its inhibition effects on glioma both in vitro and in vivo. Dox-PBCA-NP was prepared using the emulsion polymerization method. The size and size distribution of nanoparticles were measured by Malven laser mastersizer and the morphology was observed under transmission electron microscope. Drug loading (DL) and entrapment efficiency (EE) of doxorubicin in the nanoparticles were measured by UV spectra. The proliferation of C6 glioma cells was detected by MTT assay, and cell cycle was analyzed by flow cytometry. The expression of telomerase was detected by immunocytochemical analysis. The anti-tumor efficiency of Dox-PBCA-NP was assessed in C6 glioma intracranial implant rat model. The average diameter of NP-Dox was 120 nm, DL was 10.58 %, and EE was 87.43 %. We found that the cytotoxicity of Dox-PBCA-NP was lower than Dox in vitro. In vivo, Dox-PBCA-NP could transport more Dox into tumors compared to contralateral control, and the life span was longer than Dox. Moreover, Dox-PBCA-NP had less cardiotoxicity than Dox. Taken together, our results suggest that Dox-PBCA-NP exhibits better therapeutic effects against glioma and fewer side effects and is a potential nano-scale drug delivery system for glioma chemotherapy.
Literature
1.
Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre JY. Primary brain tumours in adults. Lancet. 2012;379(9830):1984–96.CrossRefPubMed
2.
Jain V, Jain S, Mahajan SC. Nanomedicines based drug delivery systems for anti-cancer targeting and treatment. Curr Drug Deliv. 2015;12(2):177–91.CrossRefPubMed
3.
Stan AC, Casares S, Radu D, Walter GF, Brumeanu TD. Doxorubicin induced cell death in highly invasive human gliomas. Anticancer Res. 1999;19(2A):941–50.PubMed
4.
Bagherpour Doun SK, Alavi SE, Koohi Moftakhari Esfahani M, Ebrahimi Shahmabadi H, Alavi F, Hamzei S. Efficacy of cisplatin-loaded poly butyl cyanoacrylate nanoparticles on the ovarian cancer: an in vitro study. Tumour Biol. 2014;35(8):7491–7.CrossRefPubMed
5.
Chaudhari KR, Ukawala M, Manjappa AS, Kumar A, Mundada PK, Mishra AK, et al. Opsonization, biodistribution, cellular uptake and apoptosis study of PEGylated PBCA nanoparticle as potential drug delivery carrier. Pharm Res. 2012;29(1):53–68.CrossRefPubMed
6.
Tian XH, Lin XN, Wei F, Feng W, Huang ZC, Wang P, et al. Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles. Int J Nanomedicine. 2011;6:445–52.PubMedPubMedCentral
7.
Ebrahimi Shahmabadi H, Movahedi F, Koohi Moftakhari Esfahani M, Alavi SE, Eslamifar A, Mohammadi Anaraki G, et al. Efficacy of cisplatin-loaded polybutyl cyanoacrylate nanoparticles on the glioblastoma. Tumour Biol. 2014;35(5):4799–806.CrossRefPubMed
8.
Liu G, Shen H, Mao J, Zhang L, Jiang Z, Sun T, et al. Transferrin modified graphene oxide for glioma-targeted drug delivery: in vitro and in vivo evaluations. ACS Appl Mater Interfaces. 2013;5(15):6909–14.CrossRefPubMed
9.
Liu G, Mao J, Jiang Z, Sun T, Hu Y, Jiang Z, et al. Transferrin-modified doxorubicin-loaded biodegradable nanoparticles exhibit enhanced efficacy in treating brain glioma-bearing rats. Cancer Biother Radiopharm. 2013;28(9):691–6.CrossRefPubMed
10.
Mao J, Li A, Zhao L, Gao L, Xu W, Hong X, et al. PEG-PLGA nanoparticles entrapping doxorubicin reduced doxorubicin-induced cardiotoxicity in rats. Adv Mater Res. 2014;912–914:263–8.CrossRef
11.
Sayed-Ahmed MM, Khattab MM, Gad MZ, Osman AM. Increased plasma endothelin-1 and cardiac nitric oxide during doxorubicin-induced cardiomyopathy. Pharmacol Toxicol. 2001;89(3):140–4.CrossRefPubMed
12.
Li M, Deng H, Peng H, Wang Q. Functional nanoparticles in targeting glioma diagnosis and therapies. J Nanosci Nanotechnol. 2014;14(1):415–32.CrossRefPubMed
13.
Pardridge WM. BBB-genomics: creating new openings for brain-drug targeting. Drug Discov Today. 2001;6(8):381–3.CrossRefPubMed
14.
De Juan BS, Von Briesen H, Gelperina SE, Kreuter J. Cytotoxicity of doxorubicin bound to poly(butyl cyanoacrylate) nanoparticles in rat glioma cell lines using different assays. J Drug Target. 2006;14(9):614–22.CrossRefPubMed
15.
Ambruosi A, Khalansky AS, Yamamoto H, Gelperina SE, Begley DJ, Kreuter J. Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats. J Drug Target. 2006;14(2):97–105.CrossRefPubMed
16.
Mitra A, Lin S. Effect of surfactant on fabrication and characterization of paclitaxel-loaded polybutylcyanoacrylate nanoparticulate delivery systems. J Pharm Pharmacol. 2003;55(7):895–902.CrossRefPubMed
17.
Karimi G, Ramezani M, Abdi A. Protective effects of lycopene and tomato extract against doxorubicin-induced cardiotoxicity. Phytother Res. 2005;19(10):912–4.CrossRefPubMed
18.
Hydock DS, Lien CY, Schneider CM, Hayward R. Exercise preconditioning protects against doxorubicin-induced cardiac dysfunction. Med Sci Sports Exerc. 2008;40(5):808–17.CrossRefPubMed
Metadata
Title
Enhanced anti-tumor effects of doxorubicin on glioma by entrapping in polybutylcyanoacrylate nanoparticles
Authors
Yuebin Zhang
Jia Yu
Lifeng Zhang
Jiabin Cai
Doute Cai
Chengjie Lv
Publication date
01-02-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4106-7

Other articles of this Issue 2/2016

Tumor Biology 2/2016 Go to the issue

Original Article

Predicting the molecular role of MEIS1 in esophageal squamous cell carcinoma

Original Article

Apoptotic effect of tannic acid on fatty acid synthase over-expressed human breast cancer cells

Review

The roles of microRNAs in Wilms’ tumors

Original Article

Diagnostic significance of S100A2 and S100A6 levels in sera of patients with non-small cell lung cancer

Original Article

The chemokine receptor CXCR7 is a critical regulator for the tumorigenesis and development of papillary thyroid carcinoma by inducing angiogenesis in vitro and in vivo

Original Article

Cancer-associated fibroblasts promote angiogenesis in gastric cancer through galectin-1 expression
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits